NASDAQ$TVRD
Tvardi Therapeutics Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Cara Therapeutics reported second quarter 2023 financial results.
Cara Therapeutics reported Q2 2023 total revenue of $6.9 million, which includes collaborative revenue of $5.4 million from KORSUVA injection sales. Net loss for the quarter was $31.5 million, or $(0.58) per basic and diluted share. The company's cash, cash equivalents, and marketable securities totaled $101.7 million as of June 30, 2023.
- Total revenue for Q2 2023 was $6.9 million, including $5.4 million in collaborative revenue from KORSUVA injection.
- KORSUVA injection vial orders increased by 46% quarter-over-quarter, indicating accelerating demand.
- Net loss for Q2 2023 was $31.5 million, or $(0.58) per basic and diluted share.
- Cash, cash equivalents, and marketable securities totaled $101.7 million as of June 30, 2023.
Headline financials
Revenue & EPS history
Tvardi Therapeutics · Revenue · Quarterly
$6.93M
Revenue by segment
Tvardi Therapeutics · $8.1M total across 1 segment · Q1 2020
- Collaboration Revenue$8.1M—100.0%
Forward guidance
The company expects its current unrestricted cash and cash equivalents and available-for-sale marketable securities, including collaborative revenue from its share of the profit from KORSUVA injection, will be sufficient to fund its currently anticipated operating plan for at least the next 12 months.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
+1.4%
Avg return
Earnings day
+1.3%
Avg return
5 days after
+0.6%
Avg return
30 days after
50%
24 / 48 earnings
Positive
+42.3%
Q3 2016
Best reaction
-34.9%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2024 | +5.0% | -2.5% | +11.3% | |
| Q3 2024 | -4.1% | -7.1% | -19.1% | |
| Q2 2024 | -3.9% | -4.1% | -22.2% | |
| Q1 2024 | +1.0% | +4.7% | -5.0% | |
| Q4 2023 | -4.2% | +3.3% | -4.5% | |
| Q3 2023 | +4.3% | +4.8% | +14.3% | |
| Q2 2023 | -6.1% | -1.9% | -31.0% | |
| Q1 2023 | +11.2% | -5.2% | -16.0% | |
| Q4 2022 | -34.9% | -41.1% | -54.2% | |
| Q3 2022 | +3.6% | +20.8% | +35.4% | |
| Q2 2022 | +4.8% | +2.1% | -2.8% | |
| Q1 2022 | +14.7% | +4.5% | +9.8% | |
| Q4 2021 | +11.2% | +3.2% | +17.2% | |
| Q3 2021 | +1.4% | -9.2% | -28.5% | |
| Q2 2021 | +1.6% | +8.4% | +21.6% | |
| Q1 2021 | +3.7% | +5.1% | +10.1% | |
| Q4 2020 | -7.4% | -4.6% | +1.6% | |
| Q3 2020 | +7.7% | +10.5% | +6.4% | |
| Q2 2020 | +2.8% | -3.9% | -8.0% | |
| Q1 2020 | +6.8% | +6.1% | +16.1% | |
| Q4 2019 | -5.2% | -6.4% | -20.6% | |
| Q3 2019 | -4.8% | +3.9% | -20.9% | |
| Q2 2019 | +8.2% | +3.6% | +6.0% | |
| Q1 2019 | -5.1% | -6.7% | -0.4% | |
| Q4 2018 | +13.7% | +7.2% | +13.7% | |
| Q3 2018 | +0.8% | +0.6% | -12.5% | |
| Q2 2018 | +6.0% | +9.6% | +11.3% | |
| Q1 2018 | -3.4% | +1.5% | +30.4% | |
| Q4 2017 | -9.2% | -15.0% | -10.1% | |
| Q3 2017 | +1.2% | +2.2% | +4.9% | |
| Q2 2017 | +22.9% | +8.1% | +4.5% | |
| Q1 2017 | -7.7% | -4.6% | +10.3% | |
| Q4 2016 | -12.3% | -10.9% | +4.1% | |
| Q3 2016 | +42.3% | +58.9% | +61.3% | |
| Q2 2016 | -1.5% | -0.7% | -12.5% | |
| Q1 2016 | -4.3% | — | — | |
| Q4 2015 | -3.8% | — | — | |
| Q3 2015 | +11.9% | — | — | |
| Q2 2015 | +4.0% | — | — | |
| Q1 2015 | -1.6% | — | — | |
| Q4 2014 | +10.2% | — | — | |
| Q3 2013 | -2.1% | — | — | |
| Q3 2014 | -2.1% | — | — | |
| Q2 2014 | -1.8% | — | — | |
| Q2 2013 | -1.8% | — | — | |
| Q1 2013 | -1.7% | — | — | |
| Q1 2014 | -1.7% | — | — | |
| Q4 2013 | -2.7% | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro